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Background
Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infec-
tion are associated with increased toxic effects in patients who also have cirrhosis. 
We evaluated the interferon-free combination of the protease inhibitor ABT-450 
with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnu-
cleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label 
phase 3 trial involving previously untreated and previously treated adults with HCV 
genotype 1 infection and compensated cirrhosis.
Methods
We randomly assigned 380 patients with Child–Pugh class A cirrhosis to receive 
either 12 or 24 weeks of treatment with ABT-450/r–ombitasvir (at a once-daily dose 
of 150 mg of ABT-450, 100 mg of ritonavir, and 25 mg of ombitasvir), dasabuvir 
(250 mg twice daily), and ribavirin administered according to body weight. The 
primary efficacy end point was a sustained virologic response 12 weeks after the 
end of treatment. The rate of sustained virologic response in each group was com-
pared with the estimated rate with a telaprevir-based regimen (47%; 95% confi-
dence interval [CI], 41 to 54). A noninferiority margin of 10.5 percentage points 
established 43% as the noninferiority threshold; the superiority threshold was 54%.
Results
A total of 191 of 208 patients who received 12 weeks of treatment had a sustained 
virologic response at post-treatment week 12, for a rate of 91.8% (97.5% CI, 87.6 to 
96.1). A total of 165 of 172 patients who received 24 weeks of treatment had a sus-
tained virologic response at post-treatment week 12, for a rate of 95.9% (97.5% CI, 
92.6 to 99.3). These rates were superior to the historical control rate. The three most 
common adverse events were fatigue (in 32.7% of patients in the 12-week group and 
46.5% of patients in the 24-week group), headache (in 27.9% and 30.8%, respec-
tively), and nausea (in 17.8% and 20.3%, respectively). The hemoglobin level was 
less than 10 g per deciliter in 7.2% and 11.0% of patients in the respective groups. 
Overall, 2.1% of patients discontinued treatment owing to adverse events.
Conclusions
In this phase 3 trial of an oral, interferon-free regimen evaluated exclusively in pa-
tients with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the 
use of three new antiviral agents and ribavirin resulted in high rates of sustained 
virologic response. Drug discontinuations due to adverse events were infrequent. 
(Funded by AbbVie; TURQUOISE-II ClinicalTrials.gov number, NCT01704755.)
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A n estimated 184 million people worldwide have hepatitis C virus (HCV) infection,1 a leading cause of chronic liver 
disease and the leading indication for liver trans-
plantation globally.2,3 Approximately 25% of per-
sons with HCV infection in the United States 
have cirrhosis, and this number is expected to 
rise to 37% by 2020.4,5 Eradication of HCV with 
antiviral therapy reduces the risk of hepatic de-
compensation, hepatocellular carcinoma, and 
death from a liver-related cause or any cause.6-10
Among patients with HCV infection and cir-
rhosis in whom peginterferon–ribavirin treatment 
has failed, rates of sustained virologic response 
to retreatment with interferon-containing regi-
mens are as low as 14%.11-19 In addition, treat-
ment for HCV infection, especially with interferon-
containing regimens, in patients with cirrhosis 
is associated with increased toxic effects.20,21 
Peginterferon–ribavirin plus telaprevir or bocepre-
vir is not recommended for patients with cir-
rhosis who have a platelet count of less than 
100,000 per cubic millimeter and an albumin 
level of less than 35 g per liter, owing to the risk 
of severe complications, including death.20 Inter-
feron-free combinations of direct-acting antiviral 
agents are therefore needed to improve the effi-
cacy and safety of HCV treatment in patients 
with cirrhosis.
ABT-450, an inhibitor of the HCV nonstruc-
tural 3/4A (NS3/4A) protease, is administered 
with ritonavir (ABT-450/r.)22 As a pharmacoen-
hancer, ritonavir has no activity against HCV; 
instead, it inhibits ABT-450 metabolism, increas-
ing peak and trough drug exposures and allow-
ing for a once-daily dose of ABT-450.23 Ombitas-
vir (ABT-267) is an HCV NS5A inhibitor, and 
dasabuvir (ABT-333) is a nonnucleoside HCV 
NS5B RNA polymerase inhibitor.22 In phase 3 
studies involving patients who had chronic HCV 
genotype 1 infection without cirrhosis, 12 weeks 
of treatment with the all-oral, interferon-free 
combination of ABT-450/r–ombitasvir and dasa-
buvir, administered with ribavirin, resulted in a 
rate of sustained virologic response of 96% 
among both previously untreated patients24 and 
patients in whom prior peginterferon–ribavirin 
treatment had failed.25
We report the results of TURQUOISE-II, a 
phase 3, randomized, open-label, international 
trial that evaluated the safety and efficacy of the 
combination of coformulated ABT-450/r–ombit-
asvir and dasabuvir with ribavirin for 12 or 24 
weeks in previously untreated and previously 
treated adults with chronic HCV genotype 1 infec-
tion and compensated cirrhosis.
Me thods
Study Patients
Patients were screened from October 24, 2012, 
through April 30, 2013, at 78 sites in North 
America and Europe. Patients 18 to 70 years of 
age were eligible for enrollment if they had previ-
ously untreated or previously treated chronic HCV 
genotype 1 infection and a plasma HCV RNA 
level of more than 10,000 IU per milliliter. Eligi-
ble patients had documentation of cirrhosis by 
means of liver biopsy (Metavir score >3 or Ishak 
score >4) or FibroScan result (≥14.6 kPa within 
6 months before screening or during screening), 
a Child–Pugh class A score of less than 7 at 
screening, and no current or past clinical evi-
dence of Child–Pugh class B or C disease. Key 
eligibility criteria were a platelet count of 60,000 
per cubic millimeter or more, a serum albumin 
level of 2.8 g per deciliter or more, a total biliru-
bin level of less than 3 mg per deciliter, an inter-
national normalized ratio of 2.3 or less, and a 
serum alpha-fetoprotein level of 100 ng per milli-
liter or less. Exclusion criteria were prior therapy 
with direct-acting antiviral agents (e.g., telaprevir 
and boceprevir) for the treatment of HCV infec-
tion and a diagnosis of hepatocellular carcinoma. 
For detailed eligibility criteria, see the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org.
Study Design and Oversight
Patients were randomly assigned in a ratio of ap-
proximately 1:1 (see the Supplementary Appen-
dix) to the 12-week or 24-week treatment group 
(Fig. S1 in the Supplementary Appendix), with 
stratification according to previous peginterferon–
ribavirin treatment for HCV infection (no vs. yes). 
Previously untreated patients were stratified ac-
cording to HCV subgenotype (1a vs. 1b) and inter-
leukin 28B (IL28B) genotype (CC vs. non-CC), a 
genetic marker associated with treatment out-
comes.26 Previously treated patients were strati-
fied according to HCV subgenotype and type of 
previous treatment failure: null response, partial 
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response, or relapse (see the Supplementary Ap-
pendix). Patients received coformulated ABT-450/r–
ombitasvir (at a once-daily dose of 150 mg of 
ABT-450, 100 mg of ritonavir, and 25 mg of ombit-
asvir) and dasabuvir (250 mg twice daily) with 
ribavirin (1000 mg or 1200 mg daily, according 
to body weight, in two doses) for 12 weeks or 
24 weeks.
The study was designed by the study investi-
gators and the sponsor (AbbVie) according to 
Good Clinical Practice guidelines, the principles 
of the Declaration of Helsinki, and applicable 
regulations, with approval by an institutional 
review board at each study site. All the patients 
provided written informed consent. The site in-
vestigators gathered the data, and the sponsor 
conducted the data analysis. The first draft of 
the manuscript was written by a medical writer 
employed by the sponsor. All the authors had 
full access to the data and participated in the 
development of the manuscript. All the authors 
confirm that the results presented are complete 
and accurate and that the study was conducted 
and reported according to the protocol (available 
at NEJM.org).
Efficacy and Safety Assessments
The collection of plasma samples and measure-
ment of HCV RNA levels are described in the 
Supplementary Appendix. Vital signs were moni-
tored, adverse events were assessed, and clinical 
laboratory testing was performed at each visit 
during the treatment and post-treatment periods. 
Adverse events were classified by the site investi-
gator as mild, moderate, or severe, and data on 
adverse events were collected from the time of 
the first dose of study medication until 30 days 
after the last dose. Data on serious adverse events 
were collected throughout the study.
Efficacy End Points
The primary efficacy end point was a sustained 
virologic response (an HCV RNA level of <25 IU 
per milliliter [the lower limit of quantitation]) 
12 weeks after the end of study-drug administra-
tion. HCV RNA levels were measured with the 
use of the COBAS TaqMan real-time reverse-tran-
scriptase–polymerase-chain-reaction assay, ver-
sion 2.0 (Roche). The primary study objectives 
were to assess the rate of sustained virologic re-
sponse in the 12-week and 24-week groups for 
noninferiority and superiority to a historical rate 
with telaprevir plus peginterferon–ribavirin among 
patients with HCV genotype 1 infection and cir-
rhosis. The key secondary efficacy end point was 
the percentage of patients with a sustained viro-
logic response in the 24-week group as compared 
with the 12-week group. Other secondary efficacy 
end points were the percentage of patients in each 
group with virologic failure during treatment or 
relapse after treatment. A gatekeeping multiple-
testing procedure (described in the Supplemen-
tary Appendix) was used for the primary efficacy 
end point and the key secondary efficacy end 
point. Rates of virologic failure during treatment 
and relapse after treatment were not part of the 
multiple-testing procedure, because no hypothe-
sis was being tested for those two end points. 
The rate of sustained virologic response at post-
treatment week 12 was also determined for pa-
tient subgroups defined according to prespecified 
baseline demographic or clinical characteristics.
Virologic failure during treatment was defined 
as two consecutive HCV RNA measurements of 
more than 1 log10 IU per milliliter above the 
nadir at any time during treatment, an HCV 
RNA level of 25 IU per milliliter or more at all 
assessments during treatment among patients 
who received at least 6 weeks of treatment, or a 
confirmed HCV RNA level of 25 IU per milliliter 
or more after a level of less than 25 IU per milli-
liter during treatment. Virologic relapse was de-
fined as a confirmed HCV RNA level of 25 IU per 
milliliter or more between the end of treatment 
and 12 weeks after the last dose of study drug 
among patients who completed treatment and 
had an HCV RNA level of less than 25 IU per 
milliliter at the final visit during the treatment 
period.
Statistical Analysis
Analyses were performed on the modified intent-
to-treat population (all randomly assigned patients 
who received at least one dose of study drugs). 
For efficacy evaluations, the percentage of pa-
tients with a sustained virologic response at post-
treatment week 12 and a two-sided 97.5% confi-
dence interval (based on the normal approximation 
to the binomial distribution) were calculated for 
each treatment group.
Rates of sustained virologic response at post-
treatment week 24 that were previously reported 
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for telaprevir11,12 were used to calculate a weight-
ed average of rates of sustained virologic response 
among previously untreated and previously treat-
ed patients, reflective of the population that we 
expected to enroll in the TURQUOISE-II study 
(see the Supplementary Appendix). The estimated 
rate used for comparison was 47% (95% confi-
dence interval [CI], 41 to 54). The noninferiority 
margin was 10.5 percentage points; for the rate 
of sustained virologic response with ABT-450/r–
ombitasvir, dasabuvir, and ribavirin to be con-
sidered noninferior, the lower confidence bound 
had to exceed 43% (equal to the upper confi-
dence bound of the historical rate with telaprevir 
plus peginterferon–ribavirin, 54%, minus 10.5 per-
centage points and rounded). For the rate of sus-
tained virologic response with ABT-450/r–ombit-
asvir, dasabuvir, and ribavirin to be considered 
superior, the lower confidence bound had to 
exceed the upper confidence bound of the his-
torical rate (54%).
The 12-week and 24-week groups were com-
pared with the use of a logistic-regression model, 
as prespecified in the protocol for the key sec-
ondary efficacy end point, with treatment group, 
baseline log10 HCV RNA level, HCV subgenotype 
(1a vs. 1b), IL28B genotype (CC vs. non-CC), and 
previous peginterferon–ribavirin treatment (no 
vs. yes) as predictors of the rate of sustained 
virologic response at post-treatment week 12. 
Rates of sustained virologic response were sum-
marized for each treatment group and random-
ization stratum to assess responses across strat-
ification variables. For exploratory purposes, a 
stepwise logistic-regression model was used to 
assess the association between the rate of sus-
tained virologic response at post-treatment week 
12 and continuous and categorical subgroup 
variables.
Statistical analyses were performed with the 
use of SAS software, version 9.3 (SAS Institute). 
A gatekeeping multiple-testing procedure was 
used to maintain a type I error rate of 0.05 for 
the analyses of the primary and key secondary 
efficacy end points (see the Supplementary Ap-
pendix, including Fig. S2). All statistical tests 
and confidence intervals were two-sided, with a 
significance level of 0.05. The number and per-
centage of patients with adverse events, abnor-
malities in laboratory values of grade 3 or 4, or 
abnormalities in hemoglobin levels were com-
pared between treatment groups with the use of 
Fisher’s exact test. For additional details, see the 
Supplementary Appendix.
R esult s
Patients
Of 671 patients assessed for eligibility, 381 were 
enrolled in the study and 380 received at least one 
dose of study drugs. Ineligibility was the most 
common reason for nonenrollment (Fig. S3 in the 
Supplementary Appendix). Baseline demographic 
and clinical characteristics were similar in the 
two treatment groups (Table 1).
Efficacy
A total of 191 of 208 patients who received 12 weeks 
of treatment had a sustained virologic response 
at post-treatment week 12, for a rate of 91.8% 
(97.5% CI, 87.6 to 96.1). A total of 165 of 172 pa-
tients who received 24 weeks of treatment had a 
sustained virologic response at post-treatment 
week 12, for a rate of 95.9% (97.5% CI, 92.6 to 
99.3) (Fig. 1). In both treatment groups, the pri-
mary efficacy end points met the prespecified 
criteria for noninferiority and superiority to the 
historical rate with telaprevir plus peginterferon–
ribavirin among patients with HCV genotype 1 
infection and cirrhosis. Rates of sustained viro-
logic response in subgroups defined by HCV sub-
genotype, status with respect to prior treatment, 
and type of treatment failure among previously 
treated patients were superior to the historical 
rate (Fig. 1). Rates did not differ substantially 
according to race, body-mass index, IL28B geno-
type, status with respect to a history of diabetes 
mellitus, status with respect to a history of de-
pression or bipolar disorder, or baseline HCV 
RNA level, platelet count, or serum albumin level 
(Table S3 in the Supplementary Appendix).
The difference in the rates of sustained viro-
logic response between the two treatment groups 
was not significant (P = 0.09) (Fig. 1). Rates were 
similar in the two treatment groups across the 
randomization strata (Table 2). Among patients 
with HCV genotype 1a infection and a prior null 
response, 39 of 42 patients in the 24-week group 
had a sustained virologic response at post-treat-
ment week 12 (92.9% [95% CI, 85.1 to 100]), as 
compared with 40 of 50 patients in the 12-week 
group (80.0% [95% CI, 68.9 to 91.1]).
A multivariate logistic-regression analysis 
showed that a prior null response to peginter-
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feron–ribavirin treatment, infection with HCV 
subgenotype 1a, and former injection-drug use 
were associated with a lower likelihood of a 
sustained virologic response at post-treatment 
week 12 (Table 3). When the self-reported vari-
able of former injection-drug use was excluded 
from the model, a prior null response and infec-
tion with HCV subgenotype 1a were still associ-
ated with a lower likelihood of a sustained viro-
logic response.
Virologic failure during treatment or relapse 
after treatment occurred in 13 of 208 patients in 
the 12-week group (6.2%) and 4 of 172 patients 
in the 24-week group (2.3%). Virologic failure 
during treatment occurred in 1 of 208 patients 
in the 12-week group (0.5% [95% CI, 0 to 1.4]) 
Table 1. Baseline Demographic and Clinical Characteristics of the Study Patients.*
Characteristic
12-Wk Group
(N = 208)
24-Wk Group
(N = 172)
Male sex — no. (%) 146 (70.2) 121 (70.3)
Race — no. (%)†
White 199 (95.7) 161 (93.6)
Black 6 (2.9) 6 (3.5)
Asian 3 (1.4) 5 (2.9)
Hispanic or Latino ethnic group — no. (%)† 25 (12.0) 20 (11.6)
Age — yr 57.1±7.0 56.5±7.9
Body-mass index‡ 27.9±4.1 27.9±4.3
HCV subgenotype — no. (%)
1a 140 (67.3) 121 (70.3)
1b 68 (32.7) 51 (29.7)
IL28B non-CC genotype — no. (%) 173 (83.2) 138 (80.2)
HCV RNA — log10 IU/ml 6.41±0.62 6.53±0.52
Prior treatment with peginterferon–ribavirin — no. (%)
Null response§ 75/122 (61.5) 62/98 (63.3)
Partial response¶ 18/122 (14.8) 13/98 (13.3)
Relapse‖ 29/122 (23.8) 23/98 (23.5)
Platelet count — ×10−9/liter
Median 140.0 142.5
Interquartile range 104.0–188.5 105.0–183.0
Serum albumin — g/liter
Median 40 39
Interquartile range 37–42 37–42
* Plus–minus values are means ±SD. Differences in baseline characteristics between the treatment groups were evaluated 
with the use of chi-square tests for categorical data and one-way analysis of variance for continuous data. There were 
no significant between-group differences in the listed baseline characteristics except for hepatitis C virus (HCV) RNA 
level (P = 0.04). Details about randomization can be found in the Supplementary Appendix.
† Race and ethnic group were self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Patients received at least 12 weeks of peginterferon–ribavirin for the treatment of HCV infection and did not have a reduc-
tion in the HCV RNA level of at least 2 log10 IU per milliliter at week 12, or they received at least 4 weeks of peginterferon–
ribavirin for the treatment of HCV infection and had a reduction in the HCV RNA level of less than 1 log10 IU per milli-
liter at week 4 (≥25 days).
¶ Patients received at least 20 weeks of peginterferon–ribavirin for the treatment of HCV infection and had a reduction in 
the HCV RNA level of 2 log10 IU per milliliter or more at week 12 but had a detectable HCV RNA level at the end of 
treatment.
‖ Patients received at least 36 weeks of peginterferon–ribavirin for the treatment of HCV infection and had an undetect-
able level of HCV RNA at the end of treatment or thereafter but a detectable level within 52 weeks after treatment.
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and in 3 of 172 patients in the 24-week group 
(1.7% [95% CI, 0 to 3.7]) (Table S4 in the Supple-
mentary Appendix). Significantly more patients 
in the 12-week group than in the 24-week group 
had a relapse: 12 of 203 patients, for a rate of 
5.9% (95% CI, 2.7 to 9.2), versus 1 of 164 pa-
tients, for a rate of 0.6% (95% CI, 0 to 1.8). 
Seven of the 12 patients with a relapse in the 
12-week group (58.3%) had HCV genotype 1a 
infection and a prior null response to peginter-
feron–ribavirin treatment.
Virologic resistance was assessed by means of 
population sequencing of samples from the 17 
patients who had virologic failure through post-
treatment week 12. At the time of virologic failure, 
2 patients had no resistance-associated variants 
detected in NS3, NS5A, or NS5B. The remaining 
15 patients had resistance-associated variants in 
two or more of the drug targets, with variants 
D168V (NS3) and Q30R (NS5A) observed most 
frequently in patients with HCV genotype 1a 
infection and D168V (NS3), Y93H (NS5A), and 
C316Y and M414I (NS5B) observed in the single 
patient with HCV genotype 1b infection.
Table 2. Sustained Virologic Response at Post-Treatment Week 12  
in Each Treatment Group, According to HCV Subgenotype and Status  
with Respect to Prior Treatment.*
Variable
12-Wk Group
(N = 208)
24-Wk Group
(N = 172)
no./total no. (%)
HCV genotype 1a infection
No prior treatment 59/64 (92.2) 52/56 (92.9)
Prior treatment
Null response 40/50 (80.0) 39/42 (92.9)
Partial response 11/11 (100) 10/10 (100)
Relapse 14/15 (93.3) 13/13 (100)
HCV genotype 1b infection
No prior treatment 22/22 (100) 18/18 (100)
Prior treatment
Null response 25/25 (100) 20/20 (100)
Partial response 6/7 (85.7) 3/3 (100)
Relapse 14/14 (100) 10/10 (100)
* Prior treatment refers to peginterferon–ribavirin for the treatment of HCV  
infection.
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Figure 1. Sustained Virologic Response at Post-Treatment Week 12 in Each Treatment Group, Overall and According to 
Subgroups.
To establish noninferiority and superiority of ritonavir-enhanced ABT-450, ombitasvir, dasabuvir, and ribavirin to the 
historical control (telaprevir plus peginterferon–ribavirin), the lower boundary of the confidence interval for the rate 
of sustained virologic response at post-treatment week 12 in each treatment group had to exceed 43% (dashed line) 
and 54% (solid line), respectively. All confidence intervals (I bars) are two-sided, with an overall alpha level of 0.05. 
For the analysis of the primary efficacy end point in the overall population, 97.5% confidence intervals were used on 
the basis of the gatekeeping multiple-testing approach; nominal 95% confidence intervals were used for subgroup 
analyses. HCV denotes hepatitis C virus.
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Safety
Adverse events were common in both groups, 
although few occurred more commonly in the 
24-week group than in the 12-week group (Table 4). 
Two percent of patients in either group discon-
tinued the study drug owing to an adverse event. 
No specific adverse event led to premature dis-
continuation by more than one patient, and no 
pattern in the types of adverse events leading to 
discontinuation was observed (Table S5 in the 
Supplementary Appendix).
The most frequent grade 3 or 4 laboratory 
abnormalities observed during the treatment 
period were elevations in total bilirubin levels 
(in 37 of 380 patients [9.7%]), which predomi-
nantly reflected elevated indirect bilirubin val-
ues; patients with such elevations did not have 
concomitant abnormalities in aminotransferase 
levels of grade 3 or 4. No grade 4 elevations in 
the total bilirubin level (i.e., >10 times the upper 
limit of the normal range) were observed. Peak 
values generally occurred after week 1 or 2 of 
treatment and declined to baseline levels by the 
end of the treatment period. Six patients (1.6%) 
had clinical jaundice, and 2 patients reported 
scleral icterus. No patient discontinued treat-
ment owing to hyperbilirubinemia.
Six patients (1.6%) had post-baseline eleva-
tions in the alanine aminotransferase level of at 
least grade 3 during treatment or within 30 days 
after the end of treatment. Four of these patients 
completed the study treatment, with normal or 
grade 1 alanine aminotransferase levels in the 
post-treatment period; all four had a sustained 
virologic response by post-treatment week 12. In 
one of the two patients who prematurely discon-
tinued the study treatment, the elevated alanine 
aminotransferase level was due to acute hepati-
tis; in the other patient, the elevation occurred 
after discontinuation of the study drug.
Grade 1 reductions in the hemoglobin level 
were common (Table 4). A total of 15 patients in 
the 12-week group (7.2%) and 19 patients in the 
24-week group (11.0%) had a hemoglobin value 
of grade 2 or higher during the treatment peri-
od. In total, 34 patients required a reduction in 
the ribavirin dose because of anemia-related 
adverse events, and all 34 had a sustained viro-
logic response at post-treatment week 12.
One patient had severe lactic acidosis in the 
context of metformin use and a subsequent ische-
mic liver injury requiring liver transplantation. 
Pathological examination of the liver revealed 
advanced cirrhosis with recent coagulative ne-
crosis of most of the cirrhotic nodules, findings 
that are characteristic of severe ischemic or hy-
poxic injury. There was no evidence of diffuse 
microvesicular steatosis (characteristic of mito-
Table 3. Logistic-Regression Analysis of Association of Subgroup Variables with a Sustained Virologic Response  
at Post-Treatment Week 12.*
Variable Estimated Odds Ratio (95% CI) P Value
Model including former injection-drug use
Previous peginterferon–ribavirin treatment (null response 
vs. partial response, relapse, or no prior treatment)
0.39 (0.16–0.94) 0.04
HCV subgenotype (1a vs. 1b) 0.12 (0.02–0.90) 0.04
Former injection-drug use (yes vs. no) 0.35 (0.14–0.86) 0.02
Model excluding former injection-drug use
Previous peginterferon–ribavirin treatment (null response 
vs. partial response, relapse, or no prior treatment)
0.33 (0.13–0.80) 0.02
HCV subgenotype (1a vs. 1b) 0.10 (0.01–0.80) 0.03
* The model including former injection-drug use also adjusted for baseline Child–Pugh score and ethnic group; the model 
excluding former injection-drug use also adjusted for geographic region and treatment duration (P>0.05). Candidate con-
tinuous variables considered were age, body-mass index, platelet count, serum albumin level, serum alpha-fetoprotein 
level, and HCV RNA level. Candidate categorical variables considered were treatment duration (12 weeks vs. 24 weeks), 
HCV subgenotype (1a vs. 1b), IL28B genotype (CC vs. non-CC), previous peginterferon–ribavirin treatment (null response 
vs. partial response, relapse, or no prior treatment), sex (female vs. male), race (black vs. nonblack), geographic region 
(Europe vs. North America), Child–Pugh score (5 vs. >5), history of diabetes (yes vs. no), history of depression or bipo-
lar disorder (yes vs. no), former injection-drug use (yes vs. no), and ethnic group (Hispanic or Latino vs. not Hispanic or 
Latino). The significance level for entering predictors into and removing predictors from the model was 0.10. P values 
are based on the Wald test. CI denotes confidence interval.
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Table 4. Adverse Events and Laboratory Abnormalities.
Variable
12-Wk Group
(N = 208)
24-Wk Group
(N = 172)
Total
(N = 380)
number of patients (percent)
Any adverse event 191 (91.8) 156 (90.7) 347 (91.3)
Adverse event leading to treatment discontinuation* 4 (1.9) 4 (2.3) 8 (2.1)
Serious adverse event† 13 (6.2) 8 (4.7) 21 (5.5)
Common adverse events‡
Fatigue 68 (32.7) 80 (46.5)§ 148 (38.9)
Headache 58 (27.9) 53 (30.8) 111 (29.2)
Nausea 37 (17.8) 35 (20.3) 72 (18.9)
Pruritus 38 (18.3) 33 (19.2) 71 (18.7)
Insomnia 32 (15.4) 31 (18.0) 63 (16.6)
Diarrhea 30 (14.4) 29 (16.9) 59 (15.5)
Asthenia 29 (13.9) 22 (12.8) 51 (13.4)
Rash 23 (11.1) 25 (14.5) 48 (12.6)
Irritability 15 (7.2) 21 (12.2) 36 (9.5)
Anemia 16 (7.7) 18 (10.5) 34 (8.9)
Dyspnea 12 (5.8) 21 (12.2)¶ 33 (8.7)
Death 1 (0.5) 0 1 (0.3)
Laboratory abnormalities‖
Alanine aminotransferase, grade 3 or 4 6 (2.9) 0¶ 6 (1.6)
Aspartate aminotransferase, grade 3 or 4 1 (0.5) 0 1 (0.3)
Alkaline phosphatase, grade 3 or 4 0 0 0
Total bilirubin, grade 3 or 4 28 (13.5) 9 (5.2)§ 37 (9.7)
Hemoglobin
Grade 1 103 (49.5) 97 (56.4) 200 (52.6)
Grade 2 12 (5.8) 18 (10.5) 30 (7.9)
Grade 3 2 (1.0) 1 (0.6) 3 (0.8)
Grade 4 1 (0.5) 0 1 (0.3)
* Adverse events leading to the discontinuation of treatment are listed in Table S5 in the Supplementary Appendix.
† Serious adverse events that occurred during the treatment period are listed in Table S6 in the Supplementary Appendix. 
An adverse event was classified as serious if it resulted in death, was life-threatening, resulted in hospitalization or pro-
longation of hospitalization, resulted in persistent or clinically significant disability or incapacity, or was an important 
medical event requiring medical or surgical intervention to prevent a serious outcome.
‡ Common adverse events were those that occurred in more than 10% of patients in either group during the treatment 
period. Events that occurred in more than 5% of patients in either group are shown in Table S7 in the Supplementary 
Appendix.
§ P<0.01 by Fisher’s exact test.
¶ P<0.05 by Fisher’s exact test.
‖ The abnormalities listed here reflect postbaseline laboratory values, regardless of baseline values. For alanine amino-
transferase, aspartate aminotransferase, and alkaline phosphatase, a level of grade 3 was defined as a value that was 
more than 5 to 20 times the upper limit of the normal range, and grade 4 as a value that was more than 20 times the 
upper limit of the normal range. A total bilirubin level of grade 3 was defined as a value that was more than 3 to 10 
times the upper limit of the normal range, and grade 4 as a value that was more than 10 times the upper limit of the 
normal range. For hemoglobin, a level of grade 1 was defined as 10 g per deciliter to less than the lower limit of the 
normal range, grade 2 as 8 to less than 10 g per deciliter, grade 3 as 6.5 to less than 8 g per deciliter, and grade 4 as 
less than 6.5 g per deciliter.
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chondrial toxic effects) or drug-induced liver 
injury. The patient died from complications after 
liver transplantation, including multiorgan fail-
ure and septic shock that began 80 days after the 
last dose of the study drug.
Discussion
This phase 3 clinical trial examined an interferon-
free, all-oral, direct-acting antiviral regimen ex-
clusively in patients with HCV genotype 1 infection 
and cirrhosis. Twelve weeks or 24 weeks of treat-
ment with coformulated ABT-450/r–ombitasvir 
and dasabuvir, administered with ribavirin, result-
ed in high rates of sustained virologic response 
at post-treatment week 12. Patients who have 
historically not been eligible for clinical trials, 
such as those with thrombocytopenia, hypoalbu-
minemia, or major depression, were included in 
this trial. Notably, approximately 15% of the study 
population had platelet counts that were clini-
cally suggestive of portal hypertension. Thus, the 
patients in this study are more broadly represen-
tative of the population of patients with cirrhosis 
than patients in previous studies have been.
The overall efficacy of 12-week and 24-week 
treatment did not differ significantly (91.8% and 
95.9%, respectively). This study included previ-
ously untreated patients and those who had 
previously been treated with peginterferon–riba-
virin. A clinically meaningful difference in the 
rates of sustained virologic response between the 
12-week and 24-week treatment groups was ob-
served among patients with HCV genotype 1a 
infection and a null response to prior peginter-
feron–ribavirin treatment. Patients with cirrhosis 
and a prior null response, a group with rates of 
sustained virologic response as low as 14% after 
retreatment with a protease inhibitor plus pegin-
terferon–ribavirin,11,18 accounted for approximate-
ly 62% of the previously treated patients enrolled 
in this trial and had rates of sustained virologic 
response of 86.7% and 95.2% in the 12-week and 
24-week groups, respectively. Specifically, patients 
with HCV genotype 1a infection and a prior null 
response had a rate of 80.0% with 12 weeks of 
treatment and 92.9% with 24 weeks of treat-
ment. All other subgroups with HCV genotype 1a 
infection, including previously untreated patients, 
those with a prior partial response, and those 
with a prior relapse, had rates of sustained viro-
logic response of 92 to 100% with 12 weeks or 
24 weeks of treatment, and patients with HCV 
genotype 1b infection and a prior null response 
had a rate of 100% with either treatment duration.
In this study, a 12-week treatment duration 
with the regimen of coformulated ABT-450/r–
ombitasvir and dasabuvir with ribavirin resulted 
in a high rate of sustained virologic response. 
Although the between-group differences among 
patients with HCV genotype 1a infection and a 
prior null response were not definitive, the nu-
merically higher rate of sustained virologic re-
sponse with the 24-week regimen suggests that 
the longer treatment duration is more effective 
in this subgroup of patients.
Declines in the hemoglobin level of grade 2 or 
higher occurred in 7.2% of patients in the 12-week 
group and in 11.0% of patients in the 24-week 
group. A 5 to 6% rate of hemoglobin decline of 
at least grade 2 has been reported among pa-
tients without cirrhosis who received the same 
regimen in phase 3 trials.24,25 For patients in both 
treatment groups, declines in the hemoglobin 
level were successfully managed with modifica-
tions in the ribavirin dose, without a negative 
effect on the rate of sustained virologic response.
Elevations in the total bilirubin level occurred 
at a higher frequency in this population of pa-
tients with cirrhosis than has been observed in 
clinical trials of the same regimen for the treat-
ment of patients without cirrhosis.24,25 Elevations 
in indirect bilirubin with this regimen are prob-
ably related to ribavirin-associated hemolysis, 
along with inhibition of the bilirubin transporter 
OATP1B1 by ABT-450, as has been reported for 
other NS3 protease inhibitors.27 Elevated biliru-
bin levels did not lead to treatment discontinua-
tion, typically peaked at about 2 weeks of treat-
ment, were not associated with elevations in the 
alanine aminotransferase level, and resolved to 
baseline levels during the post-treatment period.
The majority of adverse events were mild or 
moderate in severity, with few events occurring 
more frequently in the 24-week group than in 
the 12-week group. Serious adverse events oc-
curred in 5.5% of all patients, with similar rates 
in each group, and few patients discontinued the 
study treatment because of adverse events (2.1% 
overall). By contrast, in patients with cirrhosis, 
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interferon-containing protease-inhibitor regimens 
have been associated with a high rate of serious 
adverse events, including death, severe infection, 
hepatic decompensation, and difficult-to-treat 
anemia.20
Our study was not placebo-controlled, a de-
sign limitation that was justified because of the 
risk of hepatic decompensation among untreated 
patients. Similarly, there was no active-compara-
tor group owing to the toxic effects of standard 
interferon-containing regimens. Finally, the study 
population did not include patients who had vi-
rologic failure with other direct-acting antiviral 
therapy.
In conclusion, this multitargeted approach 
combining ritonavir-enhanced ABT-450 with om-
bitasvir, dasabuvir, and ribavirin resulted in rates 
of sustained virologic response at post-treatment 
week 12 of 92% with a 12-week regimen and 96% 
with a 24-week regimen, with a low rate of treat-
ment discontinuation, among both previously 
untreated and previously treated patients with 
HCV genotype 1 infection and compensated 
cirrhosis, a group at risk for liver-related illness 
and death.
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